

Haematologica  
HAEMATOL/2019/245167  
Version 3

SIRP $\alpha$ Fc treatment targets human acute myeloid leukemia stem cells.

Oleksandr Galkin, Jessica McLeod, James A. Kennedy, Liqing Jin,  
Nathan Mbong, Mark Wong, Robert A. Uger, Mark D. Minden, Jayne S.  
Danska, and Jean C.Y. Wang

Disclosures: R.A.U. and M.W. are employees of Trillium Therapeutics Inc. (TTI). TTI provided grant funding and drug to support this work. There is an existing license agreement between TTI and University Health Network/Hospital for Sick Children, and L.J., J.S.D. and J.C.Y.W. may be entitled to receive financial benefits further to this license and in accordance with their respective institutions' intellectual property policies.

Contributions: OG, JM, LJ, and NM performed experiments, OG, JAK, LJ performed data analysis, JSD and JCYW supervised the study, MDM provided patient samples and clinical data, OG and JCYW wrote the manuscript, MW, RAU, JSD and JCYW revised the manuscript.